Menu
Back to User profile » Dr Umberto Restelli
Papers published by Dr Umberto Restelli:
Co-Design as Enabling Factor for Patient-Centred Healthcare: A Bibliometric Literature Review
Silvola S, Restelli U, Bonfanti M, Croce D
ClinicoEconomics and Outcomes Research 2023, 15:333-347
Published Date: 17 May 2023
Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation
Restelli U, Croce D, Bonizzoni E, Marzanatti M, Andreini A, Sorio M, Tecchio C, Barison E, Benedetti F
Journal of Blood Medicine 2020, 11:123-130
Published Date: 2 April 2020
Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
Restelli U, Croce D, Pacelli V, Ciceri F, Girmenia C
Infection and Drug Resistance 2019, 12:1127-1138
Published Date: 8 May 2019
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]
Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A
Journal of Blood Medicine 2019, 10:69-70
Published Date: 8 February 2019
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A
Journal of Blood Medicine 2019, 10:21-27
Published Date: 27 December 2018
Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum]
Restelli U, Ceresoli GL, Croce D, Evangelista L, Maffioli LS, Gianoncelli L, Bombardieri E
Cancer Management and Research 2018, 10:613-614
Published Date: 27 March 2018
Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study
Restelli U, Ceresoli GL, Croce D, Evangelista L, Maffioli LS, Gianoncelli L, Bombardieri E
Cancer Management and Research 2017, 9:789-800
Published Date: 7 December 2017
Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D
ClinicoEconomics and Outcomes Research 2017, 9:569-571
Published Date: 27 September 2017
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D
Therapeutics and Clinical Risk Management 2017, 13:787-797
Published Date: 29 June 2017
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D
ClinicoEconomics and Outcomes Research 2017, 9:231-232
Published Date: 19 April 2017
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D
ClinicoEconomics and Outcomes Research 2017, 9:173-179
Published Date: 1 March 2017
Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service
Restelli U, Andreoni M, Antinori A, Bonfanti M, Di Perri G, Galli M, Lazzarin A, Rizzardini G, Croce D
ClinicoEconomics and Outcomes Research 2014, 6:409-414
Published Date: 23 September 2014